Thermostable small-molecule inhibitor of angiogenesis and vascular permeability that suppresses a pERK-FosB/ΔFosB–VCAM-1 axis
Yue Li, Ahmad M. N. Alhendi, Mei-Chun Yeh, Mina Elahy, Fernando S. Santiago, Nandan Deshpande, Ben J. Wu, Enoch Chan, Shafqat Inam, Leonel Prado-Lourenço, Jessica Marchand, Rohan D. Joyce, Lorna Wilkinson‐White, Mark J. Raftery, Meidong Zhu, Samuel Adamson, François Barnat, Karen Viaud-Quentric, Jim Sockler, Joel P. Mackay, Andrew Chang, Paul Mitchell, Sebastian M. Marcuccio, Levon M. Khachigian
Abstract
expression. BT2 reduced retinal leakage in rats at least as effectively as aflibercept, a first-line therapy for nAMD/DR. BT2 withstands boiling or autoclaving and several months' storage at 22°C. BT2 is a new small-molecule inhibitor of vascular permeability and angiogenesis.
Topics & Concepts
FOSBAngiogenesisVCAM-1Vascular permeabilityPermeability (electromagnetism)ChemistryCell biologyCancer researchBiologyBiochemistryCell adhesion moleculeEndocrinologyICAM-1Transcription factorGeneMembraneCell Adhesion Molecules ResearchAngiogenesis and VEGF in CancerRetinal Development and Disorders